

A subgroup of schizophrenia patients with motor disorders identified

January 29 2014

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

The results of the study, which was conducted in collaboration with the research team Mairena Martin at the University of Castilla La Mancha at Ciudad Real and clinical researchers of the Health Park Sant Joan de Deu at Sant Boi de Llobregat, have been published in the online edition of the *Journal of Psychiatric Research* and was funded by the TV3 Marathon in the 2008 edition.

Schizophrenia is a serious mental illness. From a clinical point of view is considered grouping several diseases that are not well defined or characterized by biomarkers.

Barrachina team studies the A2A adenosine receptor, which is highly expressed in the [basal ganglia](#) at the central nervous system and is involved in the control of movement. Furthermore this protein inhibits the activity of dopamine D2 receptor, hyperactivated in [schizophrenia patients](#) and typical antipsychotics target.

"We studied the post- mortem brains of [patients](#)," explains Barrachina "and we found that 50% had very low levels of adenosine A2A receptor. Interestingly, when comparing these data with clinical information provided by the clinical investigators of the study, we note that these

patients had motor disorders." "In addition, we identified an epigenetic mechanism associated with the decreased receptor expression."

According to the researcher, this finding allows to "identify a new subset of schizophrenia patients with motor disorders."

This study opens the door to a clinical trial, based on radioimage, which would detect the levels of this protein and identify these patients and also to confirm the results obtained in the postmortem brains of patients. Barrachina team proposes to apply a specific combination therapy of antipsychotics and agonists of A2A adenosine. "Thus, the activity of adenosine A2A receptor will be favoured, reducing the dose of antipsychotics."

More information: Villar-Menéndez I, Díaz-Sánchez S, Blanch M, Albasanz JL, Pereira-Veiga T, Monje A, Planchat LM, Ferrer I, Martín M and Barrachina M. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. *Journal of Psychiatric Research* (2014),

Related:

Aliagas E, Villar-Menéndez I, Sévigny J, Roca M, Romeu M, Ferrer I, Martín-Satué M, Barrachina M. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". *Purinergic Signal*. 2013 Dec;9(4):599-608. [DOI: 10.1007/s11302-013-9370-7](https://doi.org/10.1007/s11302-013-9370-7). Epub 2013 Jun 16. PubMed. PMID: 23771238.

Villar-Menéndez I, Blanch M, Tyebji S, Pereira-Veiga T, Albasanz JL, Martín M, Ferrer I, Pérez-Navarro E, Barrachina M. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Neuromolecular Med. 2013 Jun;15(2):295-309. [DOI: 10.1007/s12017-013-8219-0](#). Epub 2013 Feb 6. PubMed PMID: 23385980.

Provided by IDIBELL-Bellvitge Biomedical Research Institute

Citation: A subgroup of schizophrenia patients with motor disorders identified (2014, January 29) retrieved 18 April 2024 from <https://medicalxpress.com/news/2014-01-subgroup-schizophrenia-patients-motor-disorders.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.